The use of radionuclide labels allow to study the pharmacokinetics of monoclonal antibodies, to control the specificity of their targeting and to monitor the response to an antibody treatment with high accuracy. Selection of label depends on the processing of an antibody after binding to an antigen, and on the character of information to be derived from the study (distribution of antibody in the extracellular space, target occupancy or determination of sites of metabolism). This chapter provides protocols for labelling of antibodies with iodine-125 (suitable also for other radioisotopes of iodine) and with indium-111. Since radiolabelling might damage and reduce the immunoreactive fraction and/or affinity of an antibody, the methods for assessment of these characteristics of an antibody are provided for control.
Introduction
Following fate of antibodies in vivo can provide important information during preclinical development of antibody-based therapies, during clinical trials and, with the advent of personalized medicine, in daily clinical practice. The use of radioactive labels for antibodies facilitates such studies, because it is easy to quantify radioactivity concentration. Moreover, current imaging techniques, such a single photon emission computed tomography (SPECT) and positron emission tomography (PET), permit to visualise and quantify distribution of radioactivity in vivo by non-invasive procedures. Radiolabelled antibodies can be used during preclinical development for investigation of pharmacokinetics and targeting properties, dose finding and evaluation of response of treatment, hence speeding-up the process of drug discovery. The dose finding can be facilitated in clinical trials, reducing the number of patients treated with suboptimal doses of antibodies. In addition, the radiolabeled antibodies can be used for selection of patients who have tumours expressing a particular antigen and may benefit from particular therapy (1).
It has to be taken into account that labelling chemistry can influence cellular retention of radioactivity. Majority of antibodies are internalized after binding to cell-surface antigens, either by clathrin-dependent endocytosis or due to the normal turnover of cellular membrane constituents via non-clathrin-dependent endocytosis (2, 3). After internalization and translocation into lysosomal compartment, antibodies are proteolytically degraded. In vitro studies have demonstrated that the fate of a radioactive label after proteolytic degradation depends on lipophilicity of radiocatabolites (4, 5). Lipophilic radiocatabolites can diffuse through phospholipide lysosomal and cellular membranes, and leave the malignant cells. Such fate is typical for vast majority of radiohalogen labels (6). If the radiocatabolites are bulky hydrophilic (e.g. charged) molecular moiety, they would be retained inside the cells before excretion by relatively slow externalization. The radiolabels, which are trapped inside the cells after internalization and degradation of targeting protein, are called "residualizing" or "trapped". Radiometals are mainly residualizing labels (7) since their radiocatabolites are polar and often charged. Accordingly, different labels show different aspects of antibody distribution in vivo. Radioactivity associated with non-residualizing halogen labels reflects distribution of an antibody in blood, in extracellular space and bound to membranes of target cells or to extracellular matrix. Radioactivity associated with residualizing radiometal labels reflects, along with distribution of antibody outside cells, the amount of antibody, which has been internalized and degraded inside the tumour cells and by catabolizing organs.
Combination of both residualizing and non-residualizing labels for the same antibody provides the most complete information concerning its fate in vivo. Resolving gamma-spectra of radiometal and radiohalogen labels, one can derive such information from a single biodistribution study, upon co-injection in the same animal of an antibody labelled in two different ways (8).
One has to be aware that radiolabelling can influence a binding capacity of an antibody. For example, an oxidative radioiodination of antibodies using Chloramine-T (9) is the most commonly used method due to its robustness and simplicity. Radioiodide is oxidized in situ with subsequent attack of nucleophilic side-chains of a protein. A predominant site of electrophilic iodination at physiological pH is tyrosine (10). It was found (11, 12) that tyrosine residues are over-represented in complementarity determining regions (CDR) of antibodies. Iodination of tyrosines in CDR might decrease antigen binding capacity of antibodies (12). Lysines are presented in CDR to much lesser extent (13), and indirect halogenation, which is based on coupling of radiolabelled precursor to -amino groups of lysines, is often safer for proteins. However, over-modification of lysines might be also unfavourable for binding capacity and biodistribution properties of radiolabelled antibodies.
For this reason, one should take care that a number of pendant group (for radioiodination) or chelators (for radiometal labelling) should not exceed four-five per a protein molecules. After labelling of an antibody, the functional properties of antibody binding should be quantified to verify that adequate binding and acceptable immunoreactive fraction (IRF) is retained. The minimum level of quality control is to verify that the labelled protein interacts with the intended target. Since the binding properties of the unlabelled protein may be unknown, the value produced by the binding assay may serve as a characteristic of the labelled product, which can be followed over time to prove consistent performance of the labelling protocol.
The saturation assay, which estimates the equilibrium dissociation constant K D is a representative binding assay that performs well for interactions that reach equilibrium within one to a few hours. Real-time interaction analysis is a novel and more precise method for quantifying details of the binding characteristics. It is advantageous for high-affinity interactions, and requires less work than the manual binding assays, but relies on access to specialized equipment.
Another aspect of labelling quality is the immunoreactive fraction, i.e. the fraction of the labelled product, which is capable of binding to the target. The Lindmo assay (14) is the most commonly used method for assessing immunoreactive fraction.
In this chapter, we provide a description of two methods of radioiodination (a direct radioiodination using Chloramine-T (Fig.1 A) and indirect radioiodination using Nsuccinimidyl 4-thrimethylstannylbenzoate (Fig. 1B) ) and labelling with 111 In using CHX-A''-DTPA (Fig. 1C) . The most commonly used method for determination of affinity (saturation assay) and immunoreactive fraction (Lindmo analysis) of radiolabelled antibodies are also provided. In addition, a new method for determination of affinity of targeting proteins to living cells, LigandTracer analysis, is described. Besides an affinity value, this method provides information concerning association and dissociation kinetics of an antibody interaction.
[ Fig 1 near 
Methods

Purification of an antibody
Purification of antibodies is essential for all conjugation labelling techniques. Most commonly, a conjugation of a chelator or a linker is directed to an amino group of a protein.
Very often, antibody preparations contain free amino acids. The presence of free amino acids may interfere with amino-directed coupling.
1. Pre-equilibrate the NAP-5 column with Milli-Q water by passing 10 ml of Milli-Q water through the column.
2. Load 0.5 ml of the antibody solution on the column.
3. Collect and discard first 0.5 ml of eluate.
4. Add 1 ml of Milli-Q water to a column. 11. Collect the eluate as a void volume fraction.
12. Add 1 ml PBS. Collect the eluate a high molecular weight fraction containing the labelled antibody.
13. Add 1 ml PBS. Collect the eluate a low molecular weight fraction.
14. Cap the column, start with the lower end to reduce the risk of contamination. Measure activity of empty reaction mixture vial, the high molecular weight fraction, the low molecular weight fraction and the column to calculate yield according to formula
Yield = [activity of high molecular weight fraction] / [sum of all measured activities]
15. Take 14. Add 100 µl of the antibody solution to the mixture. Vortex carefully.
15. Incubate the mixture 60 min at room temperature. Calculate the mixture volume, X µl.
16. During incubation, pre-equilibrate a NAP-5 column with PBS (at least 10 ml).
17. Load the reaction mixture on the NAP-5 column and let it pass through the upper filter.
18. Add (500-X) µl PBS and let it pass through the upper filter 
Labelling of antibody with 111
In using CHX-A''DTPA
Preparation of metal-free buffers (see Note 2)
1. Prepare 0.07 M sodium borate, pH 9.3, and 0.2 M ammonium acetate, pH 5.5, using a high-quality water and p.a. reagents.
2. Add Chelex 100 (10 g per litre of buffer), mix carefully and let stay overnight.
3. Immediately before use, filter the buffer through a 0.4 µm filter into a disposable polypropylene vial. Use first 5 ml to rinse vials. Chelex 100, by passing at least 10 ml of the buffer through the column.
Conjugation of CHX-
9. Load the reaction mixture on the column. Let it pass through the upper filter.
10. Add (500-X) µl of 0.2 M ammonium acetate, pH 5.5.
11. Collect and discard the eluate.
12. Add 900 µl of 0.2 M ammonium acetate, pH 5.5, to the column, collect the eluate.
13. You can consider that all your antibody is eluted in 900 µl. Calculate the antibody concentration.
14. Divide the eluate, containing CHX-A''DTPA-cetuximab into aliquots containing 100 µg of antibody. The aliquots can be stored frozen at -20°C. C for a few days.
Labelling of CHX-
Determination of immumoreactive fraction
This protocol was established in our laboratories based on the methodology described by Lindmo and co-workers (14). We refer readers interested in the theoretical background of the method to that publication. See Notes 3-5. 12. Add 0.5 ml of the labelled antibody to each vial containing cells.
Incubate the cells with the radiolabelled antibody at 4°C for at least 4 h.
14. Form cell pellets by centrifugation (at least 5000 g for 5 min);
15. Take 0.5 ml of supernatant from each Eppendorf tube to empty Eppendorf tube, mark the tubes.
16. Measure radioactivity content in samples.
17. Measure the background radioactivity of the sample holders used for radioactivity measurement.
18. Subtract the background radioactivity to obtain a background-corrected value for each supernatant and each pellet. 9. Put culture dishes with cell on ice or move them to cold room (4°C)
Calculate cell associated radioactivity A(cells) according to
10. Add 500 µl of non-labelled antibody solution to one of cell dishes for every data point, mark. Antigens in this dish will be close to saturated, and the majority of antibody binding will be unspecific. This dish will be designated as an unspecific binding control sample.
11. Add 500 µl PBS to all other cell culture dishes.
12. Add 500 µl of the labelled antibody solution with the lowest concentration to cell culture dishes (triplicate samples plus an unspecific binding control sample), mark dishes.
13. Take one standard sample (500 µl) to a test tube, mark tube.
14. Repeat these two (12) (13) Figure 3) . We recommend using an appropriate software (e.g. GraphPad Prizm, GraphPad Software Inc). See Notes 8 and 9.
[ Fig 3 near here] 3.7. Determination of dissociation constant using LigandTracer.
LigandTracer technology has been described in a series of papers and the technical details of how to successfully conduct a real-time binding assay on living cells has been discussed elsewhere (16, 17) . Read the instrument instruction booklet prior to starting -standard operating procedures for maintaining and operating the instrument are clearly described there.
In brief, LigandTracer technology relies on a circular cell dish containing adherent cell in a limited portions, where the dish is placed on a tilted, slowly rotating support (Figure 4) . The radioactivity detector is placed over the elevated portion of the dish and registers the additional radioactivity brought under the detector by the cells. Hence, if the radiolabelled antibody binds to the cells, the detector will register an increased signal when the cells are below the detector than when the cells are out-of-view. Since the dish rotates continuously, approximately one data point per minute is collected, making it possible to follow the progress of the interaction over time.
[ Fig 4 near here] 
Cell dish preparations
1. Take an 87 mm cell dish and place it tilted on some object (a cell dish lid is usually fine).
2. Carefully dispense 1-2 ml of cell culture medium containing ~1 million adherent cells into the lower part.
3. Place in an incubator (still tilted) and let the cells attach firmly. This typically takes 8
hours, but it is strongly dependant on the cell line.
4. When the cells have attached, aspirate the medium, place the dish horizontally, add 10 ml of cell culture medium, and culture the cells for at least 24 h before using the dish.
Antibody binding measurement
1. Place the dish in the appropriate LigandTracer device and keep 3 ml of cell culture medium in the dish. Most LigandTracer assays are conducted at room temperature, but it is possible to use the device at reduced temperature (+4-8°C) if deemed necessary.
2. Start the device and collect a baseline using the default settings during 3-10 minutes. During work, the Radiation Safety guidelines set by institutions and the national nuclear regulatory authorities must be followed strictly and meticulously. Protective equipment, personal dosimeters and radiation survey monitors are required when handling any radioactive materials.
Note 2. CHX-A''DTPA has no particular selectivity for radionuclides and reacts with a broad range of transitional metals. Metal contaminations may saturate the chelator and prevent binding of radionuclides. All solution should be prepared using high quality (Milli-Q or ELGA) water. Buffers should be purified from metal contamination using Chelex 100 resin.
Colourless polypropylene Eppendorf tubes and pipette tips contain usually low level of metal impurities, and might be used directly. However, care should be taken to prevent them from dust contamination, as dust might contain metals. For some preparations with very high specific activity, reaction tubes and pipette tips might additionally treated as described by
Wadas and Anderson (20).
Note 3. Receptor expression on the selected cell line can be a limiting factor in case of low expression level or high K D value due to receptor depletion. In the sample with highest cell concentration, antigens have to be in a large excess over antibody.
Note 4.
Time to equilibrium in the antibody/antigen interaction can be another limiting factor.
In the case of slow binding kinetics, incubation time should be prolonged.
Note 5.
In the case when cell number is not a limiting factor and receptor expression is high, estimation of Immunoreactive fraction can be done using one data point with cell pellets of 1- Note 7. The accuracy of the method depends on accurate estimation of the antibody concentrations used in the experiment. Take in account that in consecutive dilutions real protein concentrations can be lower than calculated ones due to absorbance to plastic.
Therefor it is strongly recommended to take a standard sample to every added concentration and re-calculate the real concentrations based on radioactivity measurements. Illustrative examples of two incubation steps of increasing antibody concentration in a LigandTracer assay. A: Binding curve clearly approaching equilibrium at both concentrations is a strong proof for specific interaction. B: First a linear signal increase, followed by the binding curve approaching equilibrium is a strong proof for specific interaction. C: Linear signal increases at all tested concentrations can have multiple causes, including too low antibody concentration and unspecific interaction, and is hence inconclusive regarding binding properties. D: No or very small signal changes throughout the assay is usually indicative of antibody inability to bind antigens, but may also be due to insufficient number of cells. E: Square pulse like binding traces is usually indicative of antibody inability to bind antigens but can have multiple causes, including weak antibody interaction. I using the CAT protocol) interacting with HER2 expressed on SKOV3 cells, as measured using LigandTracer Grey.
